SLRN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SLRN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Acelyrin's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $644.07 Mil. Acelyrin's Total Assets for the quarter that ended in Mar. 2024 was $697.48 Mil.
The historical rank and industry rank for Acelyrin's Equity-to-Asset or its related term are showing as below:
During the past 3 years, the highest Equity to Asset Ratio of Acelyrin was 0.96. The lowest was -0.48. And the median was 0.88.
The historical data trend for Acelyrin's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acelyrin Annual Data | |||||||
Trend | Dec21 | Dec22 | Dec23 | ||||
Equity-to-Asset | -0.41 | -0.32 | 0.88 |
Acelyrin Quarterly Data | ||||||||||
Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Equity-to-Asset | Get a 7-Day Free Trial | -0.48 | 0.96 | 0.92 | 0.88 | 0.92 |
For the Biotechnology subindustry, Acelyrin's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Acelyrin's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Acelyrin's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Acelyrin's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Equity to Asset (A: Dec. 2023 ) | = | Total Stockholders Equity | / | Total Assets |
= | 656.337 | / | 742.69 | |
= |
Acelyrin's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as
Equity to Asset (Q: Mar. 2024 ) | = | Total Stockholders Equity | / | Total Assets |
= | 644.067 | / | 697.484 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acelyrin (NAS:SLRN) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Thank you for viewing the detailed overview of Acelyrin's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Shao-lee Lin | director, officer: Chief Executive Officer | C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301 |
Gil M Labrucherie | officer: Interim CFO | 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070 |
Beth C Seidenberg | director, 10 percent owner | |
Henry O Gosebruch | director | 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064-6092 |
Mardi Dier | officer: CFO and CBO | C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301 |
Mina Kim | officer: Chief Legal & Admin. Officer | C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301 |
Ronald Oyston | officer: Chief People Officer | C/O ACELYRIN, INC., 4149 LIBERTY CANYON ROAD, AGOURA HILLS CA 91301 |
Paul Peloso | officer: Chief Medical Officer | C/O ACELYRIN, INC., 4149 LIBERTY CANYON ROAD, AGOURA HILLS CA 91301 |
Dawn Svoronos | director | C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105 |
Daniel J. Becker | director | C/O NEW LEAF VENTURE PARTNERS, TIMES SQ TOWER, 7 TIMES SQ, STE 3502, NEW YORK NY 10036 |
Westlake Biopartners Fund Ii, L.p. | 10 percent owner | 3075 TOWNSGATE ROAD, SUITE 140, WESTLAKE VILLAGE CA 91361 |
Ayurmaya Capital Management Company, Lp | director, 10 percent owner, other: See Remarks | 1000 WINTER STREET, SUITE 4500, WALTHAM MA 02451 |
Sean E Harper | 10 percent owner | AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799 |
Melanie Gloria | officer: Chief Operating Officer | C/O ACELYRIN, INC., 4149 LIBERTY CANYON ROAD, AGOURA HILLS CA 91301 |
Westlake Biopartners Gp Ii, Llc | 10 percent owner | 3075 TOWNSGATE ROAD, SUITE 140, WESTLAKE VILLAGE CA 91361 |
From GuruFocus
By PRNewswire • 12-29-2023
By PRNewswire • 01-12-2024
By ACCESSWIRE • 01-10-2024
By PRNewswire • 01-09-2024
By ACCESSWIRE • 01-05-2024
By PRNewswire • 01-09-2024
By PRNewswire • 01-05-2024
By PRNewswire • 01-11-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.